Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Chemotherapy in NSCLC With Brain Metastases
NCT04768075Phase 3Completed
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- May 2021
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started May 2021; status: completed.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04768075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768075.